$7.43
3.00% yesterday
Nasdaq, Apr 03, 10:00 pm CET
ISIN
US4884451075
Symbol
ZVRA
Sector
Industry

KemPharm, Inc. Stock price

$7.43
+0.10 1.36% 1M
+0.25 3.48% 6M
-0.91 10.91% YTD
+2.40 47.71% 1Y
+2.22 42.61% 3Y
+4.23 132.07% 5Y
-171.77 95.85% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.23 3.00%
ISIN
US4884451075
Symbol
ZVRA
Sector
Industry

Key metrics

Market capitalization $402.08m
Enterprise Value $392.88m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 16.64
P/S ratio (TTM) P/S ratio 17.03
P/B ratio (TTM) P/B ratio 10.05
Revenue growth (TTM) Revenue growth -14.02%
Revenue (TTM) Revenue $23.61m
EBIT (operating result TTM) EBIT $-87.00m
Free Cash Flow (TTM) Free Cash Flow $-69.67m
Cash position $69.50m
EPS (TTM) EPS $-2.23
P/E forward negative
P/S forward 4.73
EV/Sales forward 4.62
Short interest 10.33%
Show more

Is KemPharm, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

KemPharm, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a KemPharm, Inc. forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a KemPharm, Inc. forecast:

Buy
100%

Financial data from KemPharm, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
24 24
14% 14%
100%
- Direct Costs 20 20
407% 407%
85%
3.57 3.57
85% 85%
15%
- Selling and Administrative Expenses 48 48
46% 46%
205%
- Research and Development Expense 36 36
8% 8%
151%
-81 -81
66% 66%
-341%
- Depreciation and Amortization 6.39 6.39
533% 533%
27%
EBIT (Operating Income) EBIT -87 -87
75% 75%
-369%
Net Profit -106 -106
129% 129%
-447%

In millions USD.

Don't miss a Thing! We will send you all news about KemPharm, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

KemPharm, Inc. Stock News

Neutral
GlobeNewsWire
4 days ago
Confirms Receipt of Two Director Nominees from Daniel J. Mangless Stockholders Are Not Required to Take Action at This Time CELEBRATION, Fla.
Neutral
Seeking Alpha
24 days ago
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Nichol Ochsner - VP, IR and Corporate Communications Neil McFarlane - President and CEO LaDuane Clifton - CFO Joshua Schafer - Chief Commercial Officer and EVP, Business Development Adrian Quartel - Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Jas...
Neutral
GlobeNewsWire
24 days ago
FY 2024 net revenue of $23.6 million, driven by net revenue of $12.0 million during fourth quarter of 2024 Entered into asset purchase agreement for sale of PRV for $150 million Company to host conference call and webcast today, Mar. 11, 2025, at 4:30 p.m. ET CELEBRATION, Fla.
More KemPharm, Inc. News

Company Profile

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.

Head office United States
CEO Neil McFarlane
Employees 59
Founded 2006
Website zevra.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today